Back to School: How biopharma can reboot drug development. Access exclusive analysis here

GI-5005: Additional Phase IIb data

GlobeImmune reported data from the 38 prior non-responders enrolled in an open-label Phase IIb trial showing that GI-5005 plus standard of care (SOC; Pegasys peginterferon alfa-2a and

Read the full 278 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE